Stay updated on Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial

Sign up to get notified when there's something new on the Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial page

  1. Check
    6 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    0.9%
    Check dated 2025-03-03T22:23:48.000Z thumbnail image
  4. Check
    35 days ago
    No Change Detected
  5. Check
    42 days ago
    Change Detected
    Summary
    The web page now includes a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    0.9%
    Check dated 2025-02-10T09:58:30.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.1 to 2.14.2.
    Difference
    0.1%
    Check dated 2025-02-03T08:36:45.000Z thumbnail image
  7. Check
    57 days ago
    Change Detected
    Summary
    Newly added helpful links include a study on the vaccine response in adults with atopic dermatitis, specifically focusing on Lebrikizumab (LY3650150) by Eli Lilly and Company.
    Difference
    0.6%
    Check dated 2025-01-27T03:30:57.000Z thumbnail image
  8. Check
    64 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.1%
    Check dated 2025-01-19T22:19:31.000Z thumbnail image
  9. Check
    71 days ago
    Change Detected
    Summary
    The website has been updated to include a new type of intervention in version 2.14.0, while the previous version 2.13.3 has removed the type of intervention and a study related to Lebrikizumab.
    Difference
    0.8%
    Check dated 2025-01-12T17:46:14.000Z thumbnail image

Stay in the know with updates to Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Lebrikizumab Impact on Vaccine Response in Atopic Dermatitis Clinical Trial page.